請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49746
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張正琪 | |
dc.contributor.author | Yen-Hao Chen | en |
dc.contributor.author | 陳彥豪 | zh_TW |
dc.date.accessioned | 2021-06-15T11:45:42Z | - |
dc.date.available | 2019-08-26 | |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-12 | |
dc.identifier.citation | 1.Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4-13.
2.Parise CA, Caggiano V. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. J Cancer Epidemiol. 2014;2014:469251. 3.McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 2000;321:624-8. 4.Recht A, Come SE, Gelman RS, Goldstein M. Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage, node-positive breast cancer: sequencing, timing, and outcome. J Clin Oncol. 1991;9:1662-7. 5.Jiang Q, Zheng S, Wang G. Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer. Future Med Chem. 2013;5:1023-35. 6.Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics. 2006;7:497-508. 7.Tsezou A, Tzetis M, Gennatas C, Giannatou E. Breast. 2008;17:159-66. 8.Li Y, Meeran SM, Patel SN, Chen H. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer. Mol Cancer. 2013;12:9. 9.García-Becerra R, Santos N, Díaz L, Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci. 2012;14:108-45. 10.Chen JQ, Russo J. ER alpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta. 2009;1796:162-75. 11.Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453-8. 12.Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006 ;12:895-904. 13.Ambros V. The functions of animal microRNAs. Nature. 2004;431:350-5. 14.Ibrahim T, Mercatali L, Amadori D. A new emergency in oncology: Bone metastases in breast cancer patients (Review). Oncol Lett. 2013;6:306-310. 15.Van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res. 2011;728:23-34. 16.Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem. 2003;278:21631-8. 17.Pruunsild P, Timmusk T. Structure, alternative splicing, and expression of the human and mouse KCNIP gene family. Genomics. 2005;86:581-93. 18.Xiong H, Kovacs I, Zhang Z. Differential distribution of KChIPs mRNAs in adult mouse brain. Brain Res Mol Brain Res. 2004;128:103-11. 19.Deng XY, Cai F, Xia K, Pan Q. Identification of the alternative promoters of the KChIP4 subfamily. Acta Biochim Biophys Sin. 2005;37:241-7. 20.An WF, Bowlby MR, Betty M, Cao J, Modulation of A-type potassium channels by a family of calcium sensors. Nature. 2000;403:553-6.. 21.Ohya S, Morohashi Y, Muraki K, Tomita T. Molecular cloning and expression of the novel splice variants of K(+) channel-interacting protein 2. Biochem Biophys Res Commun. 2001;282:96-102. 22.Huang X, Jan LY. Targeting potassium channels in cancer. J Cell Biol. 2014;206:151-62 23.Lansu K, Gentile S. Potassium channel activation inhibits proliferation of breast cancer cells by activating a senescence program. Cell Death Dis. 2013;4:652. 24.Potier M, Joulin V, Roger S, Besson P. Identification of SK3 channel as a new mediator of breast cancer cell migration. Mol Cancer Ther. 2006;5:2946-53. 25.Saha Roy S1, Vadlamudi RK. Role of Estrogen Receptor Signaling in Breast Cancer Metastasis. Int J Breast Cancer. 2012:654698. 26.Warner M, Nilsson S, Gustafsson JA. The estrogen receptor family. Curr Opin Obstet Gynecol. 1999;11:249-54. 27.Howell A, Robertson JF, Abram P. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22:1605-13. 28.McBride AE, Silver PA. State of the arg: protein methylation at arginine comes of age. Cell. 2001,13;106:5-8. 29.Yoshimatsu M, Toyokawa G, Hayami S. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer. 2011;128:562-73 30.Jehle J, Schweizer PA, Katus HA. Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis. 2011;2:193 31.Plummer HK, Yu Q, Cakir Y, Schuller HM. Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer. 2004;4:93. 32.Comes N, Bielanska J, Vallejo-Gracia A. The voltage-dependent K(+) channels Kv1.3 and Kv1.5 in human cancer. Front Physiol. 2013;4:283. 33.Yue W, Yager JD, Wang JP. Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids. 2013;78:161-70 34.Johnston SR1, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer. 2003;3:821-31. 35.Howell SJ, Johnston SR, Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab. 2004;18:47-66. 36.Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609-18. 37.Robertson JF1, Osborne CK, Howell A. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003;98:229-38. 38.Robertson JF, Come SE, Jones SE. Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer. 2005;41:346-56. 39.Garcia M, Derocq D, Freiss G. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci U S A. 1992;89:11538-42. 40.Yang X, Phillips DL, Ferguson AT. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001;61:7025-9. 41.Sharma D1, Saxena NK, Davidson NE. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 2006;66:6370-8. 42.Margueron R, Duong V, Bonnet S. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. J Mol Endocrinol. 2004;32:583-94. 43.Parl FF. Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer. Pharmacogenomics J. 2003;3:251-3. 44.Drummond DC, Noble CO, Kirpotin DB. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005;45:495-528. 45.Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002;13:1-13. 46.Wagner JM, Hackanson B, Lubbert M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics. 2010;1:117-136. 47.Wei H1, Mundade R1, Lange KC. Protein arginine methylation of non-histone proteins and its role in diseases. Cell Cycle. 2014;13:32-41. 48.Frankel A, Yadav N, Lee J. The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity. J Biol Chem. 2002;277:3537-43. 49.El-Andaloussi N, Valovka T, Toueille M. Methylation of DNA polymerase beta by protein arginine methyltransferase 1 regulates its binding to proliferating cell nuclear antigen. FASEB J. 2007;21:26-34. 50.Sgarra R, Lee J, Tessari MA. The AT-hook of the chromatin architectural transcription factor high mobility group A1a is arginine-methylated by protein arginine methyltransferase 6. J Biol Chem. 2006;281:3764-72. 51.Miranda TB, Webb KJ, Edberg DD. Protein arginine methyltransferase 6 specifically methylates the nonhistone chromatin protein HMGA1a. Biochem Biophys Res Commun. 2005;336:831-5. 52.Guccione E, Bassi C, Casadio F. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature. 2007;449:933-7 53.Iberg AN, Espejo A, Cheng D. Arginine methylation of the histone H3 tail impedes effector binding. J Biol Chem. 2008;283:3006-10. 54.Dreijerink KM, Mulder KW, Winkler GS. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res. 2006;66:4929-35. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49746 | - |
dc.description.abstract | 目的: 鉀離子通道作用蛋白四號屬於EF-hand protein 家族的一員,主要功能為調控A型鉀離子通道的表現,先前文獻已報導鉀離子通道在許多細胞都會有表現,也包含了癌細胞,然而這些鉀離子通道作用蛋白與癌症的關係從未釐清,本論文目標於探討鉀離子通道作用蛋白四號調控乳癌之進程及其分子機制。
實驗設計: 利用五株人類乳癌細胞株(MCF7、T47D、MDA-MB-361、SkBr-3 以及MDA-MB-231)來探討因鉀離子通道作用蛋白四號表現量被小髮夾型核醣核酸抑制或過度表現後之浸襲能力及生長能力是否受到影響。細胞移動能力之測定係利用博登細胞移行實驗分析;生長能力則使用細胞存活率分析以及流式細胞儀做測定。利用甲基化逆轉錄聚合酶反應觀察在雌激素受體的啟動子上甲基化的表現,並進一步使用染色質免疫共沉澱法來分析在雌激素受體的啟動子上相關組蛋白修飾作用的表現。動物模式實驗則是利用原位注射於乳腺脂肪墊方式來觀察抑制鉀離子通道作用蛋白四號的表現是否會影響乳癌細胞之轉移能力。 結果:實驗結果顯示鉀離子通道作用蛋白四號之表現量與乳癌病人存活率成負相關。細胞實驗發現鉀離子通道作用蛋白四號與細胞浸襲與移動能力成正相關,抑制T47D 與MDA-MB-231 中鉀離子通道作用蛋白四號的表現量會使細胞移動力明顯下降,但卻不影響細胞增生。我們進一步建立了抑制鉀離子通道作用蛋白四號之穩定MDA-MB-231 細胞株,證明抑制鉀離子通道作用蛋白四號可降低癌細胞之浸襲力。在分子機制層面,我們發現抑制鉀離子通道作用蛋白四號能顯著提升雌激素受體(ER)陰性乳癌細胞株之ER mRNA 及蛋白表現量,並且有意義提高賀爾蒙藥物之治療效果。經由核醣核酸微陣列分析找到下游分子PRMT6,過度表現該蛋白可顯著恢復細胞因鉀離子通道作用蛋白四號表現量抑制而造成移動能力的下降。利用甲基化逆轉錄聚合酶反應法,顯示在抑制鉀離子通道作用蛋白四號表現之穩定轉殖株中,雌激素受體的啟動子上甲基化的表現有明顯下降,而使用染色質免疫共沉澱法則可見雌激素受體啟動子上H3K4 trimethylation 有明顯提升。於抑制鉀離子通道作用蛋白四號之細胞株轉殖PRMT6 可回複雌激素受體之甲基化和H3K4 trimethylation。動物實驗方面,抑制鉀離子通道作用蛋白四號可明顯抑制乳癌細胞之轉移能力。 結論: 鉀離子通道作用蛋白四號可以當作乳癌臨床的癒後指標,並搭配荷爾蒙療法可作為未來治療雌激素受體陰性乳癌之治療方針 | zh_TW |
dc.description.abstract | Purpose:
K+ channel interacting protein 4 (KCNIP4) belongs to EF-hand protein superfamily which modulates A type potassium channels and regulates their surface expression. Previous studies have showed that K+ channels are expressed in a variety of cells, including cancer cells. However, the regulatory mechanism of KCNIP4 in breast cancer progression was completely unknown. Method: Human breast cancer cell lines (MCF7, T47D, MDA-MB-361, SkBr-3, and MDA-MB-231) were used as in vitro model to investigate cell invasion and proliferation by KCNIP4 expression plasmid and silenced-KCNIP4 (shKCNIP4) transfection. Boyden chamber assay was performed to check migration and invasion abilities. Proliferation ability was identified by MTT assay and flow cytometry. Methylation PCR and chromatin immunoprecipitation (ChIP) assay were performed to verify the methylation status on ER promoter and H3K4 trimethylation expression in shKCNIP4 transfectants. Mice were orthotopic injection with stable transfected KCNIP4 or vector control in MDA-MB-231 cells to measure metastasis. Results: K+ channel interacting protein 4 was negatively correlated with survival rate in breast cancer patients. KCNIP4 expression was positively correlated with invasion ability in breast cancer cells. Transiently transfected T47D and MDA-MB-231 cells with shKCNIP4 knockdown plasmids significantly reduced invasion ability (P< 0.05) but did not affect proliferation ability. Furthermore, we established shKCNIP4-stable transfectants in MDA-MB-231 cells, and found that silencing KCNIP4 could significantly down-regulated migration and invasion ability (P< 0.05) but did not affect proliferation ability. In mechanically level, silenced-KCNIP4 significantly up-regulated estrogen receptor (ER) in ERα-negative breast cancer cell lines both in mRNA level and protein level, which resulted in re-sensitizing to ER inhibitors treatment. Additionally, we performed high throughput mRNA microarray analysis and identified a downstream effecter, PRMT6. Moreover, transiently transfected PRMT6 expression plasmid could restore invasion ability in shKCNIP4 transfectants (P< 0.05). We also found that silenced-KCNIP4 decreased the methylation status on ERα promoter but overexpressed- PRMT6 in shKCNIP4 transfectants could reverse the effect. In ChIP assay, we verified that silenced-KCNIP4 could up-regulate H3K4 trimethylation expression but overexpressed-PRMT6 in shKCNIP4 transfectants turned down the effect (P< 0.05). Tumor metastasis ability was decreased in orthotopic injection in mammary fat pad with shKCNIP4 transfectants, compared with control mice in vivo. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T11:45:42Z (GMT). No. of bitstreams: 1 ntu-105-R03450017-1.pdf: 1881134 bytes, checksum: 41aae6a77a772b75fd84a62012a3a5c4 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | Abstract in Chinese…………………………………………………….i
Abstract in English……………………………………………….iii Contents……………………………………………………………………………….vi Introduction…………………………………………………………………………1 Materials and Methods……………………………………………….5 Results………………………………………………………………………………..13 Discussion………………………………………………………………………….20 Figures………………………………………………………………………………….23 Reference…………………………………………………………………………….37 | |
dc.language.iso | en | |
dc.title | 鉀離子通道作用蛋白四號於乳癌進程之角色 | zh_TW |
dc.title | The Roles of K+ Channel Interacting Protein 4 in Breast Cancer Progression | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 俞松良,郭彥彬,林季宏 | |
dc.subject.keyword | 鉀離子通道作用蛋白四號,浸襲,雌激素受體,PRMT6,乳癌, | zh_TW |
dc.subject.keyword | KCNIP4,invasion,estrogen receptor,PRMT6,breast cancer, | en |
dc.relation.page | 43 | |
dc.identifier.doi | 10.6342/NTU201602183 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 1.84 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。